What is the actual difference between retatrutide and tirzepatide?
The difference is receptor count. Both compounds are synthetic peptides engineered to bind incretin receptors — the signalling system that regulates insulin release, gastric emptying and satiety. Tirzepatide binds two of them. Retatrutide binds three.
| Tirzepatide (LY3298176) | Retatrutide (LY3437943) | |
|---|---|---|
| Class | Dual agonist | Triple agonist |
| GLP-1 receptor | Yes | Yes |
| GIP receptor | Yes | Yes |
| Glucagon receptor | No | Yes |
| Developer | Eli Lilly | Eli Lilly |
| Status | Approved medicine | Investigational — not approved |
| Largest published trial | SURMOUNT-1 (n=2,539) | TRIUMPH-1 (n=2,339) |
That third receptor is the entire point of retatrutide. Glucagon receptor agonism has been associated in published research with increased energy expenditure and reduced hepatic fat content — a mechanism the dual agonists do not engage. It is also the reason retatrutide is studied separately for metabolic dysfunction-associated steatotic liver disease.
What do the published trials report?
Both compounds now have pivotal phase 3 data at comparable scale. Read them as two independent datasets, not as two columns of one comparison.
Retatrutide TRIUMPH-1 (phase 3, 2026)
TRIUMPH-1 randomised 2,339 participants across 4 mg, 9 mg and 12 mg doses over 80 weeks. All three doses met the primary and key secondary endpoints. Mean weight change was −17.6% at 4 mg, −23.7% at 9 mg and −25.0% at 12 mg, against −3.9% on placebo. Reported adverse effects at the highest dose were predominantly gastrointestinal: nausea in 42.4% of participants, diarrhoea in 32.0%, constipation in 26.1% and vomiting in 25.3%.
A 104-week extension reported 30.3% mean weight reduction. Note that 12 mg remains the highest dose studied in published human trials.
Retatrutide phase 2 (2023)
The earlier 48-week trial randomised 338 adults with obesity across escalating doses and reported −24.2% at 12 mg. At that dose, weight reduction of at least 5%, 10% and 15% occurred in 100%, 93% and 83% of participants respectively, against 27%, 9% and 2% on placebo.
Tirzepatide SURMOUNT-1 (phase 3, 2022)
SURMOUNT-1 randomised 2,539 participants over 72 weeks including a 20-week dose-escalation period. Mean weight change was −15.0% at 5 mg, −19.5% at 10 mg and −20.9% at 15 mg, against −3.1% on placebo.
Why can’t you compare the percentages directly?
Cross-trial comparison is one of the most common errors in reading clinical literature. Four variables differ between these two datasets, and each one independently moves the headline number.
- Trial phase — phase 2 trials are smaller and typically enrol a narrower, more responsive population than phase 3.
- Duration — 48 weeks against 72 weeks. Weight-change curves in these trials had not fully plateaued at either endpoint.
- Statistical estimand — the same trial can report different percentages depending on how discontinuations are handled.
- Population baseline — differing BMI thresholds, comorbidity mix and regional composition all shift outcomes.
The two have not been directly compared in a head-to-head trial, and retatrutide is not yet approved for use.
Summary of the current evidence position, 2026
How do these compounds differ in laboratory handling?
Both arrive as lyophilised (freeze-dried) powder and share the handling profile of the wider incretin class. Neither is stable indefinitely once reconstituted.
- Lyophilised vials are stored refrigerated and protected from light; the powder is the stable form.
- Reconstitution uses bacteriostatic water, added slowly down the vial wall rather than directly onto the powder.
- Vials are swirled, never shaken — mechanical agitation shears peptide bonds.
- Purity should be verifiable against a batch-specific HPLC Certificate of Analysis, not a generic brochure figure.
Our reconstitution guide covers the full procedure and the arithmetic behind concentration, and the on-site calculator handles the conversion for a given vial size and solvent volume.